SCHEMBL369231

SCHEMBL369231

CN(C)c1cc(N2CCCOC2=O)c2nc(C(=O)NCc3ccc(F)cc3)c(OCc3ccccc3)c(=O)n2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.36
SCD O00767 1/20 0.35
CNR2 P34972 1/20 0.35
KCNH2 Q12809 1/20 0.35
CYP2C9 P11712 1/20 0.35
KMT2A Q03164 1/20 0.35
TP53 P04637 2/20 0.34
RCE1 Q9Y256 1/20 0.34
TTK P33981 1/20 0.34
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
TSHR P16473 2/20 0.33
KDM4E B2RXH2 1/20 0.33
S1PR4 O95977 1/20 0.33
S1PR1 P21453 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL368792 0.97 LMNA (0.38) LMNAL3MBTL1MAPTSMN1; SMN2SCD
SCHEMBL10070430 0.90 TP53 (0.39) LMNAMAPTSMN1; SMN2CNR2KCNH2
SCHEMBL12505473 0.88 SCD (0.39) LMNAL3MBTL1MAPTSMN1; SMN2SCD
SCHEMBL368528 0.87 LMNA (0.37) LMNAMAPTSMN1; SMN2TP53ALDH1A1
SCHEMBL10070927 0.87 TP53 (0.39) LMNASMN1; SMN2CNR2KCNH2CYP2C9
SCHEMBL367848 0.86 KCNH2 (0.45) LMNASMN1; SMN2CNR2KCNH2CYP2C9
SCHEMBL368773 0.83 NAAA (0.38) LMNASMN1; SMN2ALDH1A1HPGDTSHR
SCHEMBL360076 0.83 CYP2C9 (0.43) SMN1; SMN2CNR2KCNH2CYP2C9KMT2A
SCHEMBL367841 0.82 TP53 (0.39) LMNAL3MBTL1MAPTSMN1; SMN2SCD
SCHEMBL367528 0.81 TP53 (0.41) LMNAMAPTSMN1; SMN2SCDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) 2013-07-11 US disclosed
EP-2593460-A1 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS Avexa Limited (AU) 2013-05-22 EP disclosed
WO-2012006680-A1 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS AVEXA LIMITED (AU) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS EIF2AK2, IFNAR1, IRF3 LMNA 4293/4885L3MBTL1 4634/4885MAPT 4213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.